Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 11:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 326 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: University of Michigan Rogel Cancer Center Clear all
Active, not recruiting Phase 1 Interventional Results available

Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

NCT04477200
View directory record Official record
Conditions
Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV, Newly Diagnosed Glioblastoma, Newly Diagnosed Gliosarcoma, Newly Diagnosed Astrocytoma, Grade IV
Interventions
Mycophenolate Mofetil, Radiation Therapy, Re-resection (as part of standard of care), Temozolomide
Drug · Radiation · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 5, 2026, 11:18 PM EDT
Terminated No phase listed Observational

A Multi-Centered Trial Evaluating the Role of Vitamin D Metabolism in Non-Small Cell Lung Cancer

NCT01409681
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Oct 5, 2026, 11:18 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies

NCT02145403
View directory record Official record
Conditions
Hematologic Malignancies, Relapse, Graft-Versus-Host Disease
Interventions
Carfilzomib, Tacrolimus
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 3, 2022 · Synced Oct 5, 2026, 11:18 PM EDT
Recruiting Phase 1 Interventional

Gilteritinib for the Treatment of ALK NSCLC

NCT06225427
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Echocardiography, Gilteritinib, Magnetic Resonance Imaging, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 5, 2026, 11:18 PM EDT
Completed Not applicable Interventional Results available

Optimizing Active Surveillance in Low-Risk Prostate Cancer: a Pilot Study

NCT05764005
View directory record Official record
Conditions
Prostate Cancer
Interventions
web-based tool (MAP- Management of Active surveillance in Prostate Cancer), MUSIC website
Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
55 Years and older · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 5, 2026, 11:18 PM EDT
Completed Phase 4 Interventional Results available

VISmodegib for ORbital and Periocular Basal Cell Carcinoma

NCT02436408
View directory record Official record
Conditions
Carcinoma, Basal Cell
Interventions
Vismodegib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 5, 2026, 11:18 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer

NCT03785873
View directory record Official record
Conditions
Biliary Tract Cancer
Interventions
Nivolumab, Nanoliposomal-Irinotecan, 5-Fluorouracil, Leucovorin
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Ann Arbor, Michigan • Grand Rapids, Michigan • Salt Lake City, Utah + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 5, 2026, 11:18 PM EDT
Terminated Not applicable Interventional

Patient-centered Development of the Cancer Support Community's Open to Options ®Chatbot Program

NCT04616651
View directory record Official record
Conditions
Cancer
Interventions
Online Survey, Chatbot prototype, Open to Options (O2O) Program
Behavioral
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Oct 5, 2026, 11:18 PM EDT
Terminated Phase 2 Interventional Results available

Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)

NCT00599131
View directory record Official record
Conditions
Cancer of Larynx
Interventions
Cisplatin, Cetuximab, 5-Fluorouracil, Docetaxel
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 5, 2026, 11:18 PM EDT
Terminated Phase 2 Interventional Results available

Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer

NCT03689582
View directory record Official record
Conditions
Prostate Cancer
Interventions
68Ga-PSMA
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 5, 2026, 11:18 PM EDT
Completed Phase 2 Interventional Results available

Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

NCT04076579
View directory record Official record
Conditions
Sarcoma, Sarcoma Metastatic
Interventions
Olaparib, Trabectedin
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
16 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 5, 2026, 11:18 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial

NCT07526545
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Biopsy Procedure, Diagnostic Procedure, Electronic Health Record Review, Magnetic Resonance Imaging
Procedure · Device · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
50 Years to 75 Years · Male only
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 5, 2026, 11:18 PM EDT
Completed Not applicable Interventional

Evaluation of Tumor Factors in Breast Cancer Treated With Docetaxel and Capecitabine

NCT00156312
View directory record Official record
Conditions
Breast Cancer
Interventions
Docetaxel, Capecitabine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Oct 5, 2026, 11:18 PM EDT
Terminated Early Phase 1 Interventional

Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy

NCT03208712
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Atezolizumab, Radium-223
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 5, 2026, 11:18 PM EDT
Completed Not applicable Interventional

The Validation of a Novel Adherence Method for Oral Oncolytics

NCT03561272
View directory record Official record
Conditions
Cancer
Interventions
Smart Phone Application, POD
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 5, 2026, 11:18 PM EDT
Completed No phase listed Observational

Cognitive Function and Patient-Reported Quality of Life Outcomes Investigation in Patients Taking Vorinostat

NCT02409134
View directory record Official record
Conditions
Quality of Life, Graft-vs-Host Disease
Interventions
Not listed
Lead sponsor
Sung Choi, M.D.
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 5, 2026, 11:18 PM EDT
Terminated Phase 2 Interventional Results available

A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck

NCT01285635
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions
AT-101, Docetaxel
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 31, 2016 · Synced Oct 5, 2026, 11:18 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer

NCT00585689
View directory record Official record
Conditions
Bladder Cancer
Interventions
ABI-007, Carboplatin, Gemcitabine, Radical Cystectomy
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 30, 2015 · Synced Oct 5, 2026, 11:18 PM EDT
Recruiting Not applicable Interventional

Trial of Exercise Therapy in Familial Adenomatous Polyp (FAP)

NCT06641310
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Exercise Therapy
Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Ann Arbor, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 5, 2026, 11:18 PM EDT
Completed Phase 2 Interventional Results available

Trial Of Double Umbilical Cord Blood Transplantation

NCT00763490
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Full intensity, double umbilical cord, stem cell transplant, Flu/Bu4 conditioning regimen, Total Lymphoid Irradiation (TLI), Graft versus Host Disease prevention (GVHD prophylaxis), Mycophenolate Mofetil
Procedure · Drug · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 23, 2016 · Synced Oct 5, 2026, 11:18 PM EDT
Completed Phase 2 Interventional Results available

Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia

NCT00623935
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
Fludarabine, Busulfan, Total Body Irradiation, Stem Cell Transplant
Drug · Radiation · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
55 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 5, 2026, 11:18 PM EDT
Completed Phase 1 Interventional

Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for High Risk Prostate Cancer

NCT02946008
View directory record Official record
Conditions
Prostate Cancer
Interventions
Stereotactic Body Radiation Therapy, Radical Prostatectomy
Radiation · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 5, 2026, 11:18 PM EDT
Completed Phase 2 Interventional

Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome

NCT00005598
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
amifostine trihydrate, azacitidine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 21, 2012 · Synced Oct 5, 2026, 11:18 PM EDT
Active, not recruiting Phase 2 Interventional

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

NCT05988918
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Adenosquamous Carcinoma, Pancreatic Neuroendocrine Tumor, Pancreatic Neuroendocrine Carcinoma, Gastrointestinal Neuroendocrine Tumor, Gastrointestinal Neuroendocrine Carcinoma, Neuroendocrine Prostate Carcinoma
Interventions
ESK981
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Ann Arbor, Michigan • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 5, 2026, 11:18 PM EDT